Neutralising Assay For Mhv 68 Antibidy

Description: The PARPtrap™ Assay Kit for PARP2 is designed to measure PARP2/DNA complex formation in a high throughput screening assay using fluorescence polarization (FP). Similarly, to PARP1, PARP2 recognizes and binds damaged DNA via its DNA-binding domain. Binding to DNA activates PARP2 and in the presence of NAD+ PARP2 ribosylates itself (auto-ribosylation), which leads to PARP2 dissociation from the DNA due to the accumulated negative charge of the ribosyl polymer. In the presence of some inhibitors, however, PARP remains bound to the DNA, a phenomenon termed trapping. Trapped PARP-DNA complexes have been shown to be highly cytotoxic to cancer cells, therefore such inhibitors may be desirable for cancer treatment. The key to the PARPtrap™ Assay Kit is the fluorescent-labeled oligonucleotide duplex. In the absence of ribosylation, PARP2 binds to the fluorescent probe, forming a large complex and resulting in the emission of highly polarized light. However, after auto-ribosylation PARP2 dissociates from the oligonucleotide duplex, which then rotates freely, emitting less polarized light (Fig. 1). Addition of a PARP2 inhibitor results in trapping of PARP2 to the fluorescent oligonucleotide duplex, and increases the FP signal in a dose dependent manner.The PARPtrap™ Assay Kit is a fluorescence polarization homogeneous assay. The FP signal is measured using a fluorescent microplate reader capable of measuring fluorescence polarization.

Description: The PARPtrap™ Assay Kit for PARP2 is designed to measure PARP2/DNA complex formation in a high throughput screening assay using fluorescence polarization (FP). Similarly, to PARP1, PARP2 recognizes and binds damaged DNA via its DNA-binding domain. Binding to DNA activates PARP2 and in the presence of NAD+ PARP2 ribosylates itself (auto-ribosylation), which leads to PARP2 dissociation from the DNA due to the accumulated negative charge of the ribosyl polymer. In the presence of some inhibitors, however, PARP remains bound to the DNA, a phenomenon termed trapping. Trapped PARP-DNA complexes have been shown to be highly cytotoxic to cancer cells, therefore such inhibitors may be desirable for cancer treatment. The key to the PARPtrap™ Assay Kit is the fluorescent-labeled oligonucleotide duplex. In the absence of ribosylation, PARP2 binds to the fluorescent probe, forming a large complex and resulting in the emission of highly polarized light. However, after auto-ribosylation PARP2 dissociates from the oligonucleotide duplex, which then rotates freely, emitting less polarized light (Fig. 1). Addition of a PARP2 inhibitor results in trapping of PARP2 to the fluorescent oligonucleotide duplex, and increases the FP signal in a dose dependent manner.The PARPtrap™ Assay Kit is a fluorescence polarization homogeneous assay. The FP signal is measured using a fluorescent microplate reader capable of measuring fluorescence polarization.

Description: The PARPtrap™ Assay Kit for PARP1 is designed to measure PARP1/DNA complex formation in a high throughput screening assay using fluorescence polarization (FP). PARP1 is known to bind damaged DNA through its DNA-binding domains. Binding to DNA activates PARP1 and in the presence of NAD+ PARP1 ribosylates itself (auto-ribosylation), what in consequence leads to PARP1 dissociation from the DNA due to the accumulated negative charge of the ribosyl polymer. In the presence of some inhibitors, however, PARP remains bound to the DNA, a phenomenon termed trapping. Trapped PARP-DNA complexes have been shown to be highly cytotoxic to cancer cells, therefore such inhibitors may be desirable for cancer treatment.The key to the PARPtrap™ Assay Kit for PARP1 is the fluorescent-labeled oligonucleotide duplex. In the absence of ribosylation, PARP1 binds to the fluorescent probe, forming a large complex and resulting in the emission of highly polarized light. However, after auto-ribosylation, PARP1 dissociates from the oligonucleotide duplex, which then rotates freely, emitting less polarized light (Fig. 1). Addition of a PARP1 inhibitor results in trapping of PARP1 to the fluorescent oligonucleotide duplex, and increases the FP signal in a dose dependent manner.The PARPtrap™ Assay Kit for PARP1 is a fluorescence polarization homogeneous assay. The FP signal is measured using a fluorescent microplate reader capable of measuring fluorescence polarization.

Description: The PARPtrap™ Assay Kit for PARP1 is designed to measure PARP1/DNA complex formation in a high throughput screening assay using fluorescence polarization (FP). PARP1 is known to bind damaged DNA through its DNA-binding domains. Binding to DNA activates PARP1 and in the presence of NAD+ PARP1 ribosylates itself (auto-ribosylation), what in consequence leads to PARP1 dissociation from the DNA due to the accumulated negative charge of the ribosyl polymer. In the presence of some inhibitors, however, PARP remains bound to the DNA, a phenomenon termed trapping. Trapped PARP-DNA complexes have been shown to be highly cytotoxic to cancer cells, therefore such inhibitors may be desirable for cancer treatment.The key to the PARPtrap™ Assay Kit for PARP1 is the fluorescent-labeled oligonucleotide duplex. In the absence of ribosylation, PARP1 binds to the fluorescent probe, forming a large complex and resulting in the emission of highly polarized light. However, after auto-ribosylation, PARP1 dissociates from the oligonucleotide duplex, which then rotates freely, emitting less polarized light (Fig. 1). Addition of a PARP1 inhibitor results in trapping of PARP1 to the fluorescent oligonucleotide duplex, and increases the FP signal in a dose dependent manner.The PARPtrap™ Assay Kit for PARP1 is a fluorescence polarization homogeneous assay. The FP signal is measured using a fluorescent microplate reader capable of measuring fluorescence polarization.

Description: A sandwich ELISA kit for quantitative measurement of Rat CD68 (Cluster of Differentiation 68) in samples from Serum, Plasma, Cell supernatant

Description: Primary antibody against CD33(C33/68), APC conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD18(68-5A5), APC conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD33(C33/68), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD33(C33/68), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD18(68-5A5), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against CD18(68-5A5), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

Description: A polyclonal antibody for detection of Sam 68 from Human, Mouse, Rat. This Sam 68 antibody is for WB, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the Internal region of human Sam 68

Description: A polyclonal antibody for detection of Sam 68 from Human, Mouse, Rat. This Sam 68 antibody is for WB, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the Internal region of human Sam 68

Description: A polyclonal antibody for detection of Sam 68 from Human, Mouse, Rat. This Sam 68 antibody is for WB, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the Internal region of human Sam 68

Description: Primary antibody against CD33(C33/68), CF660R conjugate, Concentration: 0.1mg/mL